falsefalse

Post-Conference Perspectives Year in Review: 2023 Developments in Advanced or Recurrent Endometrial Cancer - Episode 3

Current Data on Single-Agent Immunotherapy in Advanced Endometrial Cancer

,

Experts review data on single-agent immunotherapy in patients with endometrial cancer from recent conferences, including ASCO 2023.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Recent Advances in Endometrial Cancer
    EP. 2: Key Takeaways From the 2023 Society of Gynecologic Oncology (SGO) Annual Meeting
    Now Viewing
    EP. 3: Current Data on Single-Agent Immunotherapy in Advanced Endometrial Cancer
    EP. 4: Dostarlimab Plus Chemotherapy for the Treatment of Advanced Endometrial Cancer: Data from the RUBY Trial
    EP. 5: Data From the AtTEnd: Study: Atezolizumab Plus Carboplatin and Paclitaxel for Treatment of Advanced Endometrial Cancer
    EP. 6: The Impact of Real-World Evidence on the Treatment of Patients With Advanced Endometrial Cancer
    EP. 7: Adverse Events Seen With Systemic Therapies in Patients With Advanced Endometrial Cancer
    EP. 8: The TROPiCS-03 Study: Sacituzumab Govitecan in Patients With Advanced Endometrial Cancer
    EP. 9: Unmet Needs in the Management of Patients With Advanced Endometrial Cancer
    EP. 10: Clinical Pearls for Community Oncologists Treating Patients With Advanced Endometrial Cancer

    Related Content:

    Post-Conference Perspectives Year in Review: 2023 Developments in Advanced or Recurrent Endometrial CancerOncLive News Network®Gynecologic Oncology
    Dr Konstantinopoulos on the Safety of Letrozole, Abemaciclib, and Metformin in ER+ Recurrent Endometrial Cancer
    Dr Eskander on Interpreting Biomarker Analyses From the DUO-E Trial in pMMR Endometrial Cancer
    Key Areas of Future Research in Advanced Melanoma
    x